Sanofi (VIE:SANO)
Austria
· Delayed Price · Currency is EUR | Market Cap | 96.43B |
| Revenue (ttm) | 46.72B |
| Net Income (ttm) | 7.81B |
| Shares Out | n/a |
| EPS (ttm) | 6.37 |
| PE Ratio | 12.34 |
| Forward PE | 9.57 |
| Dividend | 3.92 (4.87%) |
| Ex-Dividend Date | May 12, 2025 |
| Volume | 465 |
| Average Volume | 449 |
| Open | 80.51 |
| Previous Close | 80.32 |
| Day's Range | 80.18 - 80.51 |
| 52-Week Range | 76.82 - 110.34 |
| Beta | n/a |
| RSI | 52.96 |
| Earnings Date | Apr 23, 2026 |
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, COVID-19 vaccine Nuvaxovid, booster, meningitis, and travel and endemic vaccines, that in... [Read more]
Financial Performance
In 2025, Sanofi's revenue was 46.72 billion, an increase of 5.49% compared to the previous year's 44.29 billion. Earnings were 7.81 billion, an increase of 40.52%.
Financial StatementsNews
Sino Biopharm unit licenses blood cancer drug to Sanofi for up to $1.53 bln
Hong Kong-listed Sino Biopharmaceutical said on Wednesday its unit has signed an exclusive global licensing deal with French drugmaker Sanofi worth up to $1.53 billion, giving the European pharma gi...
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Sanofi and Bayer
LLY, JNJ, SNY and BAYRY ride strong pipelines and M&A momentum as Large-Cap Pharma rebounds in 2026 despite pricing and patent risks.
4 Large-Cap Pharma Stocks to Watch as Industry Recovery Gains Steam
In the Large-Cap Pharmaceuticals industry, Lilly, J&J, BAYRY and Sanofi are worth retaining as the industry shows some recovery.
Sanofi's Rilzabrutinib Gets Orphan Drug Designation In Japan For IgG4-Related Disease
(RTTNews) - Sanofi (SNY, SAN.PA, SNYNF) announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has granted orphan drug designation to Rilzabrutinib for IgG4-related disease (IgG4-RD...
Sanofi: Rilzabrutinib Granted Orphan Drug Designation In Japan For IgG4-related Disease
(RTTNews) - Sanofi (SNY, SAN.PA) announced the Ministry of Health, Labour and Welfare in Japan has granted orphan drug designation to rilzabrutinib, an oral, reversible covalent Bruton's tyrosine kina...
Sanofi: Sanofi's rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease
Sanofi's rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease Designation based on positive data from a phase 2 study of rilzabrutinib in IgG4-RDThird global orphan drug de...
Press Release: Sanofi's rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease
Sanofi's rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease Designation based on positive data from a phase 2 study of rilzabrutinib in IgG4-RD Third global orphan drug desi...
Press Release: Sanofi's rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease
Sanofi's rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease Designation based on positive data from a phase 2 study of rilzabrutinib in IgG4-RD Third global orphan drug desi...
Sanofi (SNY) Showcases Promising Ayvakit Data in Systemic Mastocytosis
Sanofi (SNY) Showcases Promising Ayvakit Data in Systemic Mastocytosis
Sanofi (SNY) and Regeneron (REGN) Gain EMA Nod for Dupixent Expansion
Sanofi (SNY) and Regeneron (REGN) Gain EMA Nod for Dupixent Expansion
Regeneron, Sanofi Receive Positive CHMP Opinion For Dupixent In Pediatric CSU
(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi SA (SNY) Friday said the European Medicines Agencys Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion fo...
Sanofi (SNY): Positive EMA Opinion for Dupixent Approval in the EU
Sanofi (SNY): Positive EMA Opinion for Dupixent Approval in the EU
Sanofi: Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment
Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment If approved, Dupixent would be the first...
Press Release: Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment
Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment If approved, Dupixent would be the first ta...
Press Release: Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment
Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment
Sanofi's Acoziborole Receives Positive CHMP Opinion For Sleeping Sickness Treatment
PARIS (dpa-AFX) - Sanofi SA (SNY) on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion for Acoziborole Winthrop for the treat...
Sanofi: Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness
Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness Recommendation based on phase 2/3...
Press Release: Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness
Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness Recommendation based on phase 2/3 s...
How Do Investors Really Feel About Sanofi SA?
Sanofi SA's (NYSE: SNY) short interest as a percent of float has fallen 5.13% since its last report. According to exchange reported data, there are now 7.94 million shares sold short , which is 0.37%...
COVID-19 Vaccine Maker Novavax Swings To Profit As Sales Climb
Novavax Inc. (NASDAQ: NVAX) shares are up on Thursday following the company’s announcement of its fourth-quarter and full-year 2025 financial results. Earnings Novavax reported fourth-quarter earning...
FDA Approves Sanofi And Regeneron's Dupixent As First Medicine For Allergic Fungal Rhinosinusitis
(RTTNews) - Sanofi (SNY, SAN.PA) said FDA has approved Dupixent or dupilumab for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis who have a his...
Regeneron, Sanofi Blockbuster Dupixent Scores FDA Nod For Rare Sinus Condition
The U.S. Food and Drug Administration on Tuesday approved Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) partnered Dupixent (dupilumab) for treating allergic fungal rhinos...
Regeneron, Sanofi Blockbuster Dupixent Scores FDA Nod For Rare Sinus Condition
• Regeneron Pharmaceuticals stock is facing resistance. Why are REGN shares declining?
Regeneron, Sanofi win Dupixent label expansion for allergic fungal rhinosinusitis
Sanofi (SNY) Gains FDA Approval for Dupixent in New Treatment Area
Sanofi (SNY) Gains FDA Approval for Dupixent in New Treatment Area